Antibiotic use is associated with SJ syndrome and toxic epidermal necrosis, with sulfonamides being the most common culprits.

Published Date: 17 Feb 2023

Antibiotic use linked to SJ syndrome and toxic epidermal necrosis, sulfonamides are worst culprits in new study...

Read Full News

Latest News

Dermocosmetics: Are Therapeutic Cosmetics Real?

From acne to rosacea, growing evidence shows targeted dermocosmetics can serve as monotherapy for mild disease or as adjunctive care, improving outcomes and treatment tolerability.

Cutaneous Appendageal Tumors: Worse Outcomes in Black People

Black patients wait weeks longer for therapy than White patients following diagnosis with rare skin cancer, and on average, deaths occur earlier.

Barriers Disrupt Isotretinoin Access in Underserved Teens

Most underserved teens report barriers to isotretinoin access, a survey found.

Adalimumab and Ixekizumab Show Similar Joint Outcomes in PsA

Adalimumab and ixekizumab show comparable effectiveness in improving joint outcomes and achieving remission in patients with psoriatic arthritis over 12 months, according to a real-world study.

Doxycycline for Acne: Impact on STIs

The lower risk for composite bacterial STI in patients taking doxycycline for acne is driven primarily by reduced risk for chlamydia, according to an analysis of TriNetX data.

India's 'Mounjaro Brides': Weight-loss Injections Become Part Of Pre-wedding Preparation

Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Latest News

From acne to rosacea, growing evidence shows targeted dermocosmetics can serve as monotherapy for mild disease or as adjunctive care, improving outcomes and treatment tolerability.

Black patients wait weeks longer for therapy than White patients following diagnosis with rare skin cancer, and on average, deaths occur earlier.

Most underserved teens report barriers to isotretinoin access, a survey found.

Adalimumab and ixekizumab show comparable effectiveness in improving joint outcomes and achieving remission in patients with psoriatic arthritis over 12 months, according to a real-world study.

The lower risk for composite bacterial STI in patients taking doxycycline for acne is driven primarily by reduced risk for chlamydia, according to an analysis of TriNetX data.

Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.

News All Time

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

Research Uncovers Mental Health Toll of Alopecia on Women

Black women are at greater risk for depression and anxiety, and scarring forms are linked to more disorders.

ICI-Related Toxicity Diagnoses Differ for Dark vs Light Skin

A review of published studies suggests that skin toxicities related to checkpoint inhibitors may be managed differently in patients with skin of color vs lighter skin tones.

Consensus Defines Vitiligo Severity, Relapse Beyond BSA

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

First-Line Biologics May Improve Psoriasis Outcomes

Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.

Pfizer-Valneva Lyme Vaccine Shows More Than 70% Efficacy but Misses Key Goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, ⁠even as it missed its main goal.

Can Mpox Vaccine Immunity Last for 5 Years?

The modified vaccinia Ankara-Bavarian Nordic vaccine induces sustained immune memory for up to 5 years, and a single booster dose at 5 years sharply raises antibody levels, a prospective study shows.

FDA Approves Dermal Filler for Temple Hollowing Indication

Loss of temple volume may be accelerated in people rapidly losing weight with medication.

Higher Mortality Risk Seen in axSpA, PsA in Real-World Study

Patients with axial spondyloarthritis and psoriatic arthritis face an elevated risk for all-cause mortality compared with the general population, and the risk is reduced with b/tsDMARD treatment.

Do Diet Trends Improve Health? A Clinical Take

Learn which diet trends have scientific support — clean eating, detox, glow food and plant-based diets influence health differently and require individualized clinical counseling.

Exclusive-Child Vaccination Rate Drops Sharply in Michigan as RFK Jr Influences Policy

Vaccination rates among young children in Michigan dropped sharply during the first year of the Trump administration, a Reuters analysis of state data shows, providing an...

FDA Approves Icotrokinra for Moderate-to-Severe Psoriasis

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

Lutikizumab Offers Relief for Refractory HS

Lutikizumab improves clinical responses and pain outcomes in patients with hidradenitis suppurativa after anti-TNF failure in a phase 2 study.

Novo Nordisk Patent Expiry Opens Door to Cheaper Weight-Loss Drugs in India

India’s diabetes and weight-loss drug market faces a shake-up as Novo Nordisk’s semaglutide patent expires, opening the door to cheaper generics.

FDA OKs Linerixibat for Cholestatic Pruritus

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

Recommended News For You

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

More nonsmokers are getting lung cancer: Oncologist explains why

What Kate Middleton Reminds Us About the Role of Privacy in Healing.

'Sugar' signatures help identify and classify pancreatic cancer cell subtypes

To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.

Hereditary cancer has a rare and underreported cause.

Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco

Recommended Articles For You

Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy 

Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development 

New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD) 

Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

2.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

3.

Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.

4.

Never in a million years did I think I'd have to limit my chemotherapy.

5.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

1.

The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition

2.

Strategic Deals and FDA Approvals Transforming U.S. Oncology Drug Development

3.

Acrochordon: What It Is, Causes, And How To Manage This Skin Condition

4.

Cancer in 2024: Global Trends, Challenges, and Innovations for Healthcare Professionals

5.

Understanding the Causes and Symptoms of Cavernous Sinus Thrombosis 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

2.

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

3.

Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion

4.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

5.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot